What the FDA labels say about taking them together
Cobicistat and irinotecan
Cobicistat's FDA label of February 10, 2026 names irinotecan in its contraindications section; the irinotecan labels PlainMeds reads (2) do not name cobicistat. The cobicistat label: “Contraindicated with TYBOST coadministered with atazanavir only: Coadministration of atazanavir with irinotecan is contraindicated due to potential for increased irinotecan toxicity.”
Check it at the source: the cobicistat FDA label on DailyMed (effective February 10, 2026, Gilead Sciences, Inc.); the irinotecan FDA label on DailyMed (effective May 12, 2026, Pharmacia & Upjohn Company LLC).
What does the cobicistat label say about irinotecan?
Cobicistat label, contraindicationsAlpha 1-adrenoreceptor antagonist: alfuzosin Antianginal: ranolazine Antiarrhythmic: dronedarone Anticonvulsants: carbamazepine, phenobarbital, phenytoin Anti-gout: colchicine Antimycobacterial: rifampin Antineoplastics: irinotecan These contraindications apply only to TYBOST coadministered with atazanavir Antipsychotics: lurasidone, pimozide Ergot Derivatives: dihydroergotamine, ergotamine, methylergonovine Herbal Products:
Cobicistat label, drug interactionsConcomitant Drug Class/Drug Name: Anticancer Agents: irinotecan; Potential Effect ↑ = Increase, ↓ = Decrease, ↔ = No change: ↑ irinotecan; Clinical Comment: Contraindicated with TYBOST coadministered with atazanavir only: Coadministration of atazanavir with irinotecan is contraindicated due to potential for increased irinotecan toxicity.
Source: FDA drug label (Tybost), Gilead Sciences, Inc., effective February 10, 2026 (SPL set 3784c35c-e87f-410c-900b-8fd6313c6010), via openFDA; the full label on DailyMed
What does the irinotecan label say about cobicistat?
Irinotecan's label (effective May 12, 2026) and its 1 other brand-application label do not name cobicistat in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Camptosar), NDA020571 (Pfizer Inc), as published by Pharmacia & Upjohn Company LLC, effective May 12, 2026 (SPL set e518dfc6-7e93-4fee-a66c-51e1ab71c056), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cobicistat | Irinotecan | |
|---|---|---|
| Labeled for | HIV | Colorectal cancer |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | n/a | n/a |
| Shortage now | A presentation being discontinued | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once